Swiss pharma giant Novartis recalls drugs in US

Swiss pharmaceutical firm Novartis said Sunday it was recalling four different products sold over the counter in the United States over reports of a malfunction at one of its plants.

The affected drugs are Excedrin, NoDoz, Bufferin and Gas-X Prevention, Novartis Consumer Health (NCH) said in a statement.

"NCH is taking this action as a precautionary measure, because the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets," it said.

"Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient.

"This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient," the statement said.

The group stressed however that it was not aware of among the affected products' consumers.

The plant in Lincoln, Nebraska where the products are manufactured was shut down last month and said improvements were being carried out there.

add to favorites email to friend print save as pdf

Related Stories

Novartis announces 2,000 job losses, profits up

Oct 25, 2011

Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Children's liquid cold, allergy medicine recalled

May 01, 2010

(AP) -- More than 40 over-the-counter infant's and children's liquid medications are being recalled in the United States and 11 other countries because they don't meet quality standards.

Buying 'legal highs' from the Internet is a risky business

May 20, 2011

Many drugs sold as 'legal highs' on the internet do not contain the ingredients they claim. Some instead contain controlled substances and are illegal to sell over the internet. These are findings of Dr. Mark Baron, who bought ...

FDA panel to vote on painkiller restrictions

Jun 30, 2009

(AP) -- Government experts are scheduled to vote on whether Nyquil and other combination cold medications should be pulled from the market to help curb deadly overdoses.

Advil or Excedrin? New model helps predict product choices

May 30, 2008

In today's world, consumers face a dizzying array of product choices. Most often, there's not just one ideal product; it depends on the individual and the context. A beer might be perfect for relaxing after work; a sports ...

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

Mar 03, 2015

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

Mar 03, 2015

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.